Science ❯ Medical Research ❯ Vaccine Efficacy ❯ Safety Studies
The authorization brings the first U.S.‑licensed mRNA seasonal flu vaccine but its public rollout is uncertain because the CDC advisory panel cannot meet to set formal recommendations.
